Changes to This Summary (08/02/2011)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about pegylated interferon alpha-2b, which was approved by the U.S. Food and Drug Administration in 2011 for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of complete surgical resection, including complete lymphadenectomy. Also stated that approval was based on EORTC-18991 and that relapse-free survival was improved for patients receiving interferon. Added that one-third of the patients receiving pegylated interferon discontinued treatment because of toxicity.
Back to Top
